OpGen - OPGN Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPGN shares.
View OPGN analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1-year target prices for OpGen's shares. Their OPGN share price forecasts range from $1.25 to $3.00. On average, they predict the company's share price to reach $2.13 in the next twelve months. This suggests a possible upside of 1,533.4% from the stock's current price.
View analysts price targets for OPGN or view top-rated stocks among Wall Street analysts.

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 87.0% and is now trading at $0.1301.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our OPGN earnings forecast.

OpGen, Inc. (NASDAQ:OPGN) released its quarterly earnings data on Thursday, November, 11th. The medical research company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The medical research company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $1.20 million. OpGen had a negative trailing twelve-month return on equity of 91.83% and a negative net margin of 1,016.12%. During the same period in the previous year, the business posted ($0.40) earnings per share.

Shares of OpGen reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

OpGen issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.50 million-$3.00 million, compared to the consensus revenue estimate of $4.51 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.87%), Vanguard Group Inc. (3.50%), Renaissance Technologies LLC (0.22%) and Citadel Advisors LLC (0.19%). Insiders that own company stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends.

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPGN stock can currently be purchased for approximately $0.13.

OpGen (NASDAQ:OPGN) has a market capitalization of $6.99 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for the company is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.